This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

proofread

Pathogenesis to management of hepatocellular carcinoma

Genes & Cancer | Pathogenesis to management of hepatocellular carcinoma
Molecular pathways and targeted therapeutics in hepatocellular carcinoma. Abbreviations: APC: antigen presenting cell; AXL is a cell surface receptor tyrosine kinase, part of the TAM family of kinases; CD: cluster differentiation; CTLA4: cytotoxic T-lymphocyte–assoc+iated antigen 4; ERK: extracellular signal-regulated kinase; FGFR: Fibroblast growth factor receptors; KIT: tyrosine-protein kinase; MEK: mitogen-activated protein kinase; MET: Mesenchymal Epithelial Transition; PDGFR: platelet-derived growth factor receptor; PD-L1: Programmed cell death ligand 1; RAF: rapidly accelerated fibrosarcoma; Tie2 is a receptor tyrosine kinase; VEGF: Vascular endothelial growth factor. Credit: Genes & Cancer (2022). DOI: 10.18632/genesandcancer.226

A new review was published in Genes & Cancer on December 13, 2022, entitled, "Pathogenesis to management of hepatocellular carcinoma." In this review, researchers from multiple universities and medical centers across the U.S. discussed hepatocellular carcinoma (HCC)—the most common primary liver cancer, whose incidence continues to rise in many parts of the world due to a concomitant rise in many associated risk factors, such as alcohol use and obesity.

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer death. Although early-stage HCC can be potentially curable through liver resection, liver-directed therapies, or transplantation, patients usually present with intermediate to advanced disease, which continues to be associated with a poor prognosis. This is because HCC is a cancer with significant complexities, including substantial clinical, histopathologic, and genomic heterogeneity. However, the has made a major effort to better characterize HCC in those aspects via utilizing tissue sampling and histological classification, , and developing viable animal models.

These efforts ultimately aim to develop clinically relevant biomarkers and discover for new therapies. For example, until recently, there was only one approved systemic therapy for advanced or metastatic HCC in the form of sorafenib. Through these efforts, several additional targeted therapies have gained approval in the United States, although much progress remains to be desired.

More information: Ben L. Da et al, Pathogenesis to management of hepatocellular carcinoma, Genes & Cancer (2022). DOI: 10.18632/genesandcancer.226

Provided by Impact Journals
Citation: Pathogenesis to management of hepatocellular carcinoma (2023, January 6) retrieved 18 June 2024 from https://medicalxpress.com/news/2023-01-pathogenesis-hepatocellular-carcinoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

AGA recommends shared decision-making approach for treatment of hepatocellular carcinoma

2 shares

Feedback to editors